These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29249543)

  • 21. Influenza A(H3N2) Antibody Responses to Standard-Dose Versus Enhanced Influenza Vaccine Immunogenicity in Older Adults and Prior Season's Vaccine Status.
    Zhong S; Ng TWY; Skowronski DM; Iuliano AD; Leung NHL; Perera RAPM; Ho F; Fang VJ; Tam YH; Ip DKM; Havers FG; Fry AM; Aziz-Baumgartner E; Barr IG; Peiris M; Thompson MG; Cowling BJ
    J Infect Dis; 2024 May; 229(5):1451-1459. PubMed ID: 37950884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
    Ganczak M; Dubiel P; Drozd-Dąbrowska M; Hallmann-Szelińska E; Szymański K; Brydak LB
    Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31739554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of immunogenicity between candidate influenza A(H3N2) virus vaccine strains in Japan: A randomized controlled trial using a monovalent vaccine of A/Saitama/103/2014 (CEXP-002) and A/Hong Kong/4801/2014 (X-263).
    Kase T; Inoue M; Morikawa S; Kumashiro H; Hiroi S; Nakata K; Ito K; Ishibashi M; Tsuru T; Irie S; Maeda A; Ohfuji S; Fukushima W; Hirota Y
    Vaccine; 2020 Sep; 38(42):6524-6532. PubMed ID: 32873406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-dependent cell-mediated cytotoxicity antibody responses to inactivated and live-attenuated influenza vaccination in children during 2014-15.
    Florek K; Mutschler J; McLean HQ; King JP; Flannery B; Belongia EA; Friedrich TC
    Vaccine; 2020 Feb; 38(8):2088-2094. PubMed ID: 31753674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low population serum microneutralization antibody titer against the predominating influenza A(H3N2) N121K virus during the severe influenza summer peak of Hong Kong in 2017.
    Zhu H; Lee ACY; Li C; Mak WWN; Chen YY; Chan KH; Zhang AJX; Fung WF; Zhang RQ; Fung YF; Poon RWS; Lam JY; Tam S; Hung IFN; Chen H; Yuen KY; To KKW
    Emerg Microbes Infect; 2018 Mar; 7(1):23. PubMed ID: 29511175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poor Immunogenicity, Not Vaccine Strain Egg Adaptation, May Explain the Low H3N2 Influenza Vaccine Effectiveness in 2012-2013.
    Cobey S; Gouma S; Parkhouse K; Chambers BS; Ertl HC; Schmader KE; Halpin RA; Lin X; Stockwell TB; Das SR; Landon E; Tesic V; Youngster I; Pinsky BA; Wentworth DE; Hensley SE; Grad YH
    Clin Infect Dis; 2018 Jul; 67(3):327-333. PubMed ID: 29471464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
    Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014-2015 Influenza Vaccine.
    Petrie JG; Malosh RE; Cheng CK; Ohmit SE; Martin ET; Johnson E; Truscon R; Eichelberger MC; Gubareva LV; Fry AM; Monto AS
    Clin Infect Dis; 2017 Oct; 65(10):1644-1651. PubMed ID: 29020179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Previous-Season Influenza Vaccination on Serologic Response in Children During 3 Seasons, 2013-2014 Through 2015-2016.
    McLean HQ; King JP; Talley P; Flannery B; Spencer S; Levine MZ; Friedrich TC; Belongia EA
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):173-180. PubMed ID: 30759228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-protection against homologous drift variants of influenza A and B after vaccination with split vaccine.
    Heckler R; Baillot A; Engelmann H; Neumeier E; Windorfer A
    Intervirology; 2007; 50(1):58-62. PubMed ID: 17164559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018.
    Belongia EA; Levine MZ; Olaiya O; Gross FL; King JP; Flannery B; McLean HQ
    Vaccine; 2020 Mar; 38(15):3121-3128. PubMed ID: 32145994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seasonal Influenza Vaccination of Children Induces Humoral and Cell-Mediated Immunity Beyond the Current Season: Cross-reactivity With Past and Future Strains.
    Reber AJ; Kim JH; Coleman LA; Spencer SM; Chung JR; Chen J; Gargiullo P; Sundaram ME; Belongia EA; Shay DK; Katz JM; Sambhara S
    J Infect Dis; 2016 Nov; 214(10):1477-1486. PubMed ID: 27571905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
    Frenck RW; Belshe R; Brady RC; Winokur PL; Campbell JD; Treanor J; Hay CM; Dekker CL; Walter EB; Cate TR; Edwards KM; Hill H; Wolff M; Leduc T; Tornieporth N
    Vaccine; 2011 Aug; 29(34):5666-74. PubMed ID: 21699951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of age and recent influenza vaccination history on the immunogenicity and efficacy of 2009-10 seasonal trivalent inactivated influenza vaccination in children.
    Ng S; Ip DK; Fang VJ; Chan KH; Chiu SS; Leung GM; Peiris JS; Cowling BJ
    PLoS One; 2013; 8(3):e59077. PubMed ID: 23554974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain.
    Mendelman PM; Rappaport R; Cho I; Block S; Gruber W; August M; Dawson D; Cordova J; Kemble G; Mahmood K; Palladino G; Lee MS; Razmpour A; Stoddard J; Forrest BD
    Pediatr Infect Dis J; 2004 Nov; 23(11):1053-5. PubMed ID: 15545863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
    Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
    Front Immunol; 2018; 9():2465. PubMed ID: 30405641
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2-16 years after successive annual vaccinations with LAIV.
    Hoschler K; Maharjan S; Whitaker H; Southern J; Okai B; Baldevarona J; Turner PJ; Andrews NJ; Miller E; Zambon M
    Vaccine; 2020 Mar; 38(12):2660-2670. PubMed ID: 32070679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children.
    Black S; Nicolay U; Vesikari T; Knuf M; Del Giudice G; Della Cioppa G; Tsai T; Clemens R; Rappuoli R
    Pediatr Infect Dis J; 2011 Dec; 30(12):1081-5. PubMed ID: 21983214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.